It is hypothesized that the use of PSMA-PET/CT in addition to prostate MRI could improve the detection of prostate cancer as it may unveil additional tumors in negative MRI examinations (PI-RADS 1–2) and could avoid biopsies in men with equivocal MRI findings (PI-RADS 3). This evidence concerns the gene FOLH1 and prostate cancer.